LexDanaLexDanabeta
Inventor

William J. Greenlee

Inventor
Teaneck, NJ, US

Overview

142→
Patents
1981–2021
Patent span
Chemistry
Primary field (CPC C)

Patents· 142 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds43%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
A61KPreparations for medical, dental or toiletry purposes13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium6%
C07CAcyclic or carbocyclic compounds4%
C07KPeptides3%
Y02ATechnologies for adaptation to climate change1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
A01NPreservation of bodies of humans or animals or plants or parts thereof0%
C04BLime, magnesia0%
PatentTitleYear
11,124,516Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders202111,084,800Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders202111,083,720Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases202110,869,871Compositions and methods of modulating short-chain dehydrogenase activity202010,807,952Compounds for treatment of immune inflammatory disorders202010,787,454Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders202010,662,175Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders20209,914,727'Factor IXa inhibitors'20189,789,116'Compositions and methods of modulating short-chain dehydrogenase activity'20179,708,308'Factor IXa inhibitors'20179,695,198'Factor IXa inhibitors'20179,409,918'Bridged bicyclic piperidine derivatives and methods of use thereof'20169,340,530'Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists'20169,301,929'Substituted biaryl derivatives and methods of use thereof'20169,278,965'Bridged and fused antidiabetic compounds'20169,161,924'Factor IXa inhibitors'20159,096,582'Gamma secretase modulators'20158,987,242'Morpholinone compounds as factor IXA inhibitors'20158,933,116'Gamma secretase inhibitors'20158,912,206'Pyrimidine ether derivatives and methods of use thereof'20148,907,095'Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119'20148,829,036'Heterocyclic aspartyl protease inhibitors'20148,822,480'Bicyclic heterocycle derivatives and use thereof as GPR119 modulators'20148,815,876'Bicyclic heterocycle derivatives and methods of use thereof'20148,809,318'Gamma secretase modulators'20148,778,980'Heterocyclic aspartyl protease inhibitors'20148,735,604'Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use'20148,722,708'Substituted isoindolines as aspartyl protease inhibitors'20148,691,831'Heterocyclic aspartyl protease inhibitors'20148,691,833'Heterocyclic aspartyl protease inhibitors'20148,673,900'Gamma secretase modulators'20148,642,582'Morpholinone compounds as factor IXa inhibitors'20148,623,873'Substituted piperazines as CB1 antagonists'20148,623,818'Glucagon receptor antagonists, compositions, and methods for their use'20148,609,676'4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors'20138,580,807'Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders'20138,580,956'Gamma secretase modulators'20138,518,975'Gamma secretase modulators'20138,487,099'Gamma secretase modulators'20138,470,773'Thiophenes as glucagon receptor antagonists, compositions, and methods for their use'20138,450,343'Gamma secretase modulators'2013RE044205'Adenosine A2a receptor antagonists'20138,426,403'Gamma secretase modulators'20138,361,959'Spiro-imidazolone derivatives as glucagon receptor antagonists'20138,357,682'Gamma secretase modulators'20138,242,112'Heterocyclic aspartyl protease inhibitors'20128,236,805'Substituted piperazines as CB1 antagonists'20128,183,252'Heterocyclic aspartyl protease inhibitors'20128,178,513'Heterocyclic aspartyl protease inhibitors'20128,148,363'Heterocyclic compounds as factor IXA inhibitors'20127,973,067'Heterocyclic aspartyl protease inhibitors'20117,897,601'Cannabinoid receptor modulators'20117,868,000'Aspartyl protease inhibitors'20117,763,609'Heterocyclic aspartyl protease inhibitors'20107,713,999'Thrombin receptor antagonists'20107,700,597'Substituted piperazines as CB1 antagonists'20107,700,603'Heterocyclic aspartyl protease inhibitors'20107,687,501'Pyridothienopyridazinone derivatives as mGluR1 antagonists'20107,592,348'Heterocyclic aspartyl protease inhibitors'20097,511,146'2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20097,504,391'Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders'20097,459,450'Neuropeptide receptor modulators'20087,442,712'Constrained himbacine analogs as thrombin receptor antagonists'20087,304,078'Thrombin receptor antagonists'20077,211,574'Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders'20076,916,811'Adenosine A2a receptor antagonists'20056,897,216'Adenosine A2a receptor antagonists'20056,894,063'Substituted urea neuropeptide Y Y5 Receptor antagonists'20056,890,936'Muscarinic antagonists'20056,630,475'Adenosine A2a receptor antagonists'20036,384,224'Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands'20026,331,629'Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands'20016,040,448'Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands'20005,767,310'Phenoxyphenylacetic acid derivatives'19985,686,478'Endothelin antagonists'19975,668,176'Phenoxyphenylacetic acid derivatives'19975,565,485'Biphenyl compounds useful or endothelin antagonists'19965,559,135'Endothelin antagonists bearing pyridyl amides'19965,554,625'Substituted biphenylmethylimidazopyridines'19965,538,991'Endothelin antagonists bearing 5-membered heterocyclic amides'19965,527,819'Inhibitors of HIV reverse transcriptase'19965,449,682'Angiotensin II antagonists incorporating a substituted benzyl element'19955,441,959'Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists'19955,411,980'Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists'19955,412,097'Heterocyclic compounds bearing acidic functional groups as angiotensin II antagonists'19955,401,745'Quinazolinones substituted with phenoxyphenylacetic acid derivatives'19955,389,660'Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists'19955,385,894'Disubstituted 6-aminoquinazolinones'19955,348,955'N,N-diacylpiperazines'19945,344,830'N,N-diacylpiperazine tachykinin antagonists'19945,336,778'Substituted triazoles as angiotensin II antagonists'19945,334,598'Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives'19945,332,744'Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists'19945,330,987'Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists'19945,324,729'Substituted pyrimidines, pyrimidinones and pyridopyrimidines'19945,312,820'Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines'19945,292,726'N,N-diacylpiperazines'19945,281,614'Substituted 1,2,4-triazoles bearing acidic functional groups as angiotensin II antagonists'19945,264,439'Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element'19935,262,412'Substituted pyrazoles, compositions and use'19935,260,285'Substituted imidazopyridazines as angiotensin II antagonists'19935,254,682'Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs'19935,250,521'Substituted pyrazolopyrimidines as angiotensin II antagonists'19935,246,944'Quinoline angiotensin II antagonists incorporating a substituted benzyl element'19935,240,928'Substituted quinazolinones as angiotensin II antagonists'19935,240,938'Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring'19935,238,942'Substituted quinazolinones bearing acidic functional groups as angiotensin II antagonists'19935,236,928'Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists'19935,223,501'Substituted pyrimidinones bearing acidic functional groups as angiotensin II antagonists'19935,223,499'6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists'19935,202,328'Substituted fused pyrimidinones'19935,194,605'Cyclic renin inhibitors containing 2-substituted (3S,4S)-4-amino-5-cyclohexyl-3-hydroxy pentanoic acid, 2-substituted (3S,4S)-5-cyclohexyl-3,4-di-hydroxy pentanoic acid or 2-substituted (4S,5S)-5-amino-6-cyclohexyl-4-hydroxyhexanoic acid or its analogs'19935,187,159'Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole'19935,183,810'Imidazole angiotensin II antagonists incorporating a substituted benzyl element'19935,177,095'Triazole angiotensin II antagonists incorporating a substituted benzyl element'19935,175,164'Angiotensin II antagonists incorporating a substituted indole or dihydroindole'19925,166,206'Substituted pyrimidines, pyrimidinones and pyridopyrimidines'19925,164,407'Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin II antagonsists'19925,162,340'Substituted 1-(2H)-isoquinolinones bearing acidic functional groups as angiotensin II antagonists'19925,157,040'Substituted quinolines as angiotensin II antagonists'19925,157,026'Oxo-purines as angiotensin II antagonists'19925,151,435'Angiotensin II antagonists incorporating an indole or dihydroindole'19925,126,342'Imidazole angiotensin II antagonists incorporating acidic functional groups'19925,124,335'Substituted pyrollo-fused 6 membered heterocycles as angiotensin II antagonists'19925,124,327'HIV reverse transcriptase'19925,102,880'Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists'19925,100,897'Substituted pyrimidinones as angiotensin II antagonists'19925,064,825'Angiotensin II antagonists'19915,049,548'Renin-inhibitory di-, tri-, and tetrapeptides'19915,039,664'Renin inhibitors containing phenylalanyl-histidine replacements'19915,037,807'Renin inhibitors containing phenylalanyl-histidine replacements'19915,006,511'Di- or tripeptide renin inhibitors containing lactam conformational restriction in achpa'19914,866,087'Carboxyalkyl urea compounds and derivatives thereof useful as angiotensin converting enzyme inhibitors and as antihypertensives'19894,839,357'Renin inhibitors containing phenylalanyl-histidine replacements'19894,788,322'Process for preparing ACHPA'19884,634,715'Aza analogs of carboxyalkyl dipeptide derivatives as antihypertensives'19874,576,748'3-Hydroxy-3-aminoethyl .beta.-lactams'19864,442,030'Process for preparing carboxyalkyl dipeptides'19844,402,969'Antihypertensive proline derivatives'19834,379,146'Substituted phosphonamides as antihypertensives'19834,347,375'Process for preparing amino acids and esters'19824,275,220'Process for preparing amino acids and esters'1981

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1981–1998Patents assigned to MERCK & CO INC (69)· patent assignee history
1981–1982Based in New York, NY, US· patent location history
1983–2021Based in Teaneck, NJ, US· patent location history
2003–2012Patents assigned to SCHERING CORP (23)· patent assignee history
2012–2016Patents assigned to GREENLEE WILLIAM J (33)· patent assignee history
2012–2015Patents assigned to ZHU ZHAONING (16)· patent assignee history
2013–2018Patents assigned to MERCK SHARP & DOHME (32)· patent assignee history
2017–2020Based in Cleveland, OH, US· patent location history
2021Based in New Haven, CT, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
MERCK & CO INC691981–1998
GREENLEE WILLIAM Jself332012–2016
MERCK SHARP & DOHME322013–2018
SCHERING CORP232003–2012
ZHU ZHAONING162012–2015
Locations
LocationPatentsSpan
Teaneck, New Jersey, US1371983–2021
Cleveland, OH, US22017–2020
New York, New York, US21981–1982
New Haven, CT, US12021